Bladder cancer stage I with carcinoma in situ represents a particularly challenging form of bladder cancer, combining tumors that have grown into deeper layers of the bladder wall with flat, high-grade cancer cells spread across the bladder’s inner lining. Understanding treatment options, both established and experimental, helps patients and their families navigate this complex diagnosis with greater confidence.

Understanding This Unique Cancer Combination

When bladder cancer is classified as stage I with carcinoma in situ, patients are facing two distinct types of cancer at once. Stage I bladder cancer means the tumor has grown through the bladder’s inner lining into the layer of connective tissue underneath, but has not yet reached the muscular wall of the bladder.^[1] This is sometimes called non-muscle-invasive bladder cancer because it stays outside the muscle layer that gives the bladder its structure.^[2]

Carcinoma in situ, often shortened to CIS, is a flat cancer that spreads like a thin sheet across the surface of the bladder’s inner lining rather than growing inward or forming a visible lump.^[3] The term “in situ” means “in its original place,” indicating the cancer has not moved deeper into the bladder wall or spread to other parts of the body.^[3] Even though CIS is classified as stage 0, the earliest stage of bladder cancer, it is always considered high-grade, meaning the cancer cells look very abnormal under a microscope and tend to be aggressive.^[3]

The combination of stage I disease with CIS creates a particularly high-risk situation. Approximately 10% of patients with bladder cancer present with CIS at diagnosis, representing about 6,400 to 6,800 people in the United States each year.^[3] When CIS appears alongside stage I cancer, the risk of the cancer returning after treatment or progressing to more advanced stages is higher than with stage I disease alone.^[6]

Patients with this combination often experience urinary symptoms that can be quite bothersome. While blood in the urine is the most common symptom of bladder cancer overall, people with CIS frequently experience additional uncomfortable symptoms including painful urination, frequent urination, a sudden urgent need to urinate, or even urine leaking suddenly.^[3] These symptoms occur because the flat cancer cells irritate the bladder lining, even though CIS itself has not grown deeper into the bladder wall.

Standard Treatment Approaches

The first line of treatment for stage I bladder cancer with carcinoma in situ begins with a surgical procedure called transurethral resection, often abbreviated as TUR.^[2] This procedure serves multiple purposes at once: it confirms the diagnosis, determines how deep the cancer has grown, and removes as much visible cancer as possible. During a TUR, a urologist inserts a thin, lighted tube called a cystoscope into the bladder through the urethra, the tube that carries urine out of the body. Through this tube, the surgeon can examine the bladder lining and remove tissue samples or cancerous areas using electrical current (cautery) or laser energy.^[2]

Sometimes a second TUR is necessary if the first surgery did not remove enough tumor tissue or did not include a sample from the muscle layer of the bladder wall.^[8] This repeat procedure helps ensure doctors have accurate information about how far the cancer has spread. If the second surgery reveals the cancer has actually invaded the muscle layer, treatment approaches change significantly because muscle-invasive bladder cancer behaves differently and requires more aggressive therapy.^[8]

Surgery alone is rarely enough for this type of bladder cancer. Because stage I cancer with CIS carries a high risk of returning after surgery, additional treatment is almost always recommended.^[8] The standard approach approved by both the American Urological Association and the European Association of Urology involves intravesical therapy, meaning medication delivered directly into the bladder.^[6]

The most effective intravesical treatment for high-risk bladder cancer including stage I with CIS is bacillus Calmette-Guérin, commonly known as BCG.^[6] BCG is actually a weakened form of bacteria related to tuberculosis that stimulates the body’s immune system to attack cancer cells in the bladder. After the initial TUR surgery, BCG is inserted into the bladder through a catheter, where it stays for a period of time before being emptied out when the patient urinates. This treatment is typically given once a week for six weeks as an initial course.^[8]

BCG therapy has proven remarkably effective at reducing the risk of cancer progression. Studies have shown that after BCG treatment, the risk of CIS progressing to invasive disease drops to 9.8%, compared to much higher rates without treatment.^[6] Because of its superior effectiveness compared to other agents, BCG is considered the standard first-line treatment for high-risk bladder cancer including cases with CIS.^[6]

To help prevent the cancer from returning, doctors often recommend continuing BCG therapy for an extended period, called maintenance therapy. For high-risk bladder cancer with CIS, maintenance BCG may continue for up to three years, depending on the specific characteristics of the cancer.^[8] This long-term treatment significantly lowers the chance of recurrence compared to the initial six-week course alone.

BCG treatment can cause side effects because it works by stimulating an immune response in the bladder. Many patients experience bladder irritation symptoms including frequent urination, burning during urination, or urgent need to urinate, especially in the hours after treatment. Some people develop flu-like symptoms such as fever, fatigue, or body aches. These side effects are generally temporary and indicate the treatment is activating the immune system. However, serious side effects can occasionally occur, and patients should contact their doctor if they develop high fever, severe flu-like symptoms that last more than two days, or blood in the urine that persists beyond a few days after treatment.^[11]

An alternative to BCG for intravesical therapy involves chemotherapy drugs, most commonly mitomycin or gemcitabine.^[8] These medications kill cancer cells directly rather than working through the immune system. Intravesical chemotherapy may be given at the time of the initial surgery or as ongoing treatment afterward. While chemotherapy is effective, particularly for intermediate-risk bladder cancers, BCG remains the preferred choice for high-risk cases including stage I with CIS.^[8]

For patients who cannot tolerate intravesical therapy or whose cancer does not respond to it, surgery to remove part or all of the bladder may be necessary. A segmental cystectomy removes only the section of the bladder containing cancer and is rarely used for multiple superficial cancers.^[2] More commonly, radical cystectomy, the complete removal of the bladder, is recommended as second-line treatment when BCG therapy fails.^[6] This is considered the standard second-line therapy according to American Urological Association and European Association of Urology guidelines because other treatments have not proven as effective at preventing cancer progression.^[6]

Monitoring and Surveillance

After treatment for stage I bladder cancer with CIS, close monitoring is essential because this type of cancer has a tendency to return. Surveillance typically includes regular cystoscopies, where a camera is inserted into the bladder to visually inspect the lining for any signs of cancer recurrence.^[8] These inspections may be performed every three to six months initially, with the frequency gradually decreasing over time if no cancer is detected.

Additional imaging tests may also be used to monitor for cancer recurrence or progression. The goal of this careful surveillance is to catch any returning cancer at the earliest possible stage when it is most treatable.^[8] Patients should understand that even with successful treatment, bladder cancer can recur. Within 15 to 20 years, more than half of surviving patients will experience progressive cancer or develop new cancers, including cancers of the upper urinary tract.^[2] This long-term risk makes ongoing surveillance a lifelong commitment for many bladder cancer survivors.

Treatment Options in Clinical Trials

For patients whose cancer does not respond to BCG therapy or who cannot undergo radical cystectomy due to other health conditions or personal preferences, clinical trials offer hope through experimental treatments. Researchers are actively investigating new therapies that could provide alternatives to surgery or improve outcomes when standard treatments fail.

One area of active research involves different approaches to intravesical therapy for patients who have failed BCG treatment. These are often referred to as therapies for “BCG-unresponsive” or “BCG-refractory” disease. While these treatments remain experimental and are typically tested in clinical trials, they represent important options for patients who have run out of standard treatment choices.^[6]

Clinical trials for bladder cancer are testing various types of innovative treatments. Immunotherapy drugs that work differently from BCG are being studied to see if they can stimulate the immune system in new ways to fight bladder cancer. Some trials examine drugs delivered into the bladder while others test medications given by injection or pill that travel through the bloodstream to reach cancer cells.

The trials typically follow a structured progression through three phases. Phase I trials focus on safety, determining what dose of a new drug can be given safely and identifying potential side effects. Phase II trials examine whether the treatment actually works against cancer, measuring things like tumor shrinkage or prevention of cancer recurrence. Phase III trials compare the new treatment directly with current standard therapies to determine if it offers better outcomes.

Researchers are also exploring gene therapy approaches that attempt to correct or modify the genetic changes that allow cancer cells to grow. These experimental treatments are designed to target specific molecular pathways involved in bladder cancer development and progression. Some gene therapy trials use modified viruses to deliver therapeutic genes directly into bladder cells, attempting to restore normal cell function or trigger cancer cell death.

Another area of investigation involves combinations of different intravesical therapies. Researchers are testing whether using two or more drugs together in the bladder might be more effective than single agents. These combination approaches aim to attack cancer cells through multiple mechanisms simultaneously, potentially overcoming resistance that develops to single treatments.

Clinical trials for bladder cancer are conducted at medical centers throughout the United States, Europe, and other parts of the world. Eligibility for specific trials depends on many factors including the stage and grade of cancer, previous treatments received, overall health status, and specific characteristics of the tumor. Patients interested in clinical trials should discuss options with their urologist or oncologist, who can help identify appropriate studies and explain the potential benefits and risks of participation.

Participation in clinical trials offers access to promising new treatments before they become widely available. However, it is important to understand that experimental treatments have not yet been proven effective and may have unknown side effects. Patients in trials are closely monitored by research teams and typically receive more frequent examinations and tests than those receiving standard care. This intensive monitoring can actually be a benefit, catching any problems early.

Most common treatment methods

• Surgical removal of cancer
  • Transurethral resection (TUR) using cystoscope inserted through the urethra to remove visible cancer with electrical current or laser energy^[2]
  • Segmental cystectomy removing part of the bladder for extensive superficial cancers (rarely used)^[2]
  • Radical cystectomy removing the entire bladder, recommended as second-line treatment when BCG therapy fails^[6]
  • Repeat TUR if first surgery did not remove adequate tissue or include muscle layer sample^[8]
• Intravesical immunotherapy
  • Bacillus Calmette-Guérin (BCG) therapy delivered directly into the bladder to stimulate immune response against cancer cells^[6]
  • Initial treatment typically once weekly for six weeks after TUR surgery^[8]
  • Maintenance BCG therapy continued for up to three years to prevent recurrence in high-risk cases^[8]
  • Reduces risk of progression to invasive disease from over 50% to 9.8%^[6]
• Intravesical chemotherapy
  • Mitomycin or gemcitabine delivered into the bladder through catheter^[8]
  • May be given at time of initial surgery or as ongoing treatment afterward^[8]
  • Works by directly killing cancer cells rather than stimulating immune response
  • Alternative option for patients who cannot tolerate BCG therapy
• Close surveillance monitoring
  • Regular cystoscopy examinations to visually inspect bladder lining for recurrence^[8]
  • Imaging tests to monitor for cancer progression or spread
  • Typically performed every 3-6 months initially, with decreasing frequency over time^[8]
  • Lifelong monitoring needed due to high risk of recurrence^[2]
• Experimental treatments in clinical trials
  • Novel immunotherapy approaches for BCG-unresponsive disease^[6]
  • Gene therapy targeting specific molecular pathways in cancer cells
  • Combination intravesical therapies using multiple drugs simultaneously
  • Available at medical centers in United States, Europe, and worldwide

Factors Affecting Treatment Decisions

Many factors influence which treatment approach is best for an individual patient. The specific characteristics of the cancer play a major role, including exactly how deep it has grown, whether multiple tumors are present, the size of tumors, and whether CIS is limited to one area or spread widely across the bladder lining.^[8] High-grade tumors, multiple tumors, large tumors, or widespread CIS all point toward more aggressive treatment.

The patient’s overall health and personal preferences are equally important in treatment planning. Radical cystectomy is major surgery that significantly impacts quality of life, requiring reconstruction of how the body stores and eliminates urine. Some patients are not healthy enough for major surgery due to heart disease, lung disease, or other medical conditions. Others may be physically able but choose to avoid surgery if possible. For these patients, continued intravesical therapy or participation in clinical trials may be preferable options.^[6]

The cancer’s response to initial treatment also guides future decisions. If cancer responds well to BCG therapy with no signs of recurrence during maintenance treatment, surveillance may continue with the bladder intact. However, if cancer returns despite BCG therapy or continues to progress, more aggressive intervention becomes necessary.^[6] The timing and pattern of recurrence matter as well—cancer that returns quickly after treatment tends to be more aggressive than cancer that recurs many years later.^[19]

Living With This Diagnosis

A diagnosis of stage I bladder cancer with carcinoma in situ requires patients to become partners in their long-term care. The high risk of recurrence means bladder cancer survivors must commit to regular follow-up appointments and surveillance procedures, sometimes for the rest of their lives. This ongoing monitoring can feel burdensome, but it provides the best chance of catching any returning cancer early when treatment is most likely to succeed.

Lifestyle modifications may help reduce recurrence risk. For patients who smoke, quitting is one of the most important steps they can take, as smoking is associated with about half of all bladder cancers and increases recurrence risk.^[13] Staying well hydrated by drinking plenty of fluids helps dilute the urine and may reduce irritation to the bladder lining. Some studies suggest that maintaining a healthy diet rich in fruits and vegetables while limiting processed red meat consumption may have modest benefits.^[13]

The emotional impact of living with bladder cancer should not be underestimated. Anxiety about recurrence is common and normal. Many patients find it helpful to connect with support groups where they can share experiences with others facing similar challenges. Talking with a counselor or therapist who specializes in cancer care can provide coping strategies for managing fear and uncertainty.

Patients should maintain open communication with their healthcare team about any new symptoms that develop. Blood in the urine, pain or burning during urination, increased urinary frequency or urgency, or back pain could indicate cancer recurrence and warrant prompt evaluation. However, some of these symptoms may also result from bladder irritation from treatment or unrelated conditions, so patients should not panic but should report changes to their doctor.